3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
18
Carcinoma, Non-Small-Cell Lung
17
Urinary Bladder Neoplasms
14
Lung Neoplasms
11
Ovarian Neoplasms
10
Nasopharyngeal Carcinoma
9
Neoplasm Metastasis
8
Lymphoma, Large B-Cell, Diffuse
6
Cholangiocarcinoma
6
Biliary Tract Neoplasms
6
Non-Muscle Invasive Bladder Neoplasms
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Transitional Cell
4
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urologic Neoplasms
2
Sarcoma
2
Rectal Neoplasms
2
Osteosarcoma
2
Melanoma
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Leiomyosarcoma
2
Interventions
Bevacizumab
11
durvalumab
9
atezolizumab
9
Specimen Handling
9
tremelimumab
8
lenvatinib
7
Nivolumab
6
Magnetic Resonance Spectroscopy
5
X-Rays
4
Sorafenib
3
Oxaliplatin
3
Ipilimumab
3
Fluorouracil
3
tislelizumab
2
sapanisertib
2
relatlimab
2
cabozantinib
2
Surgical Procedures, Operative
2
Radiation
2
Leucovorin
2
Immunotherapy
2
Immunoglobulin G
2
Doxorubicin
2
Disulfides
2
Carboplatin
2
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
sofosbuvir-velpatasvir drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Gemcitabine
×
30 days
×
Clear all
NCT03017326
2026-05-13
PHITT
University of Birmingham
Phase 3
Active not recruiting
450 enrolled